Clinical Trial Update: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating BL-M11D1 for relapsed/refractory acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BL-M11D1

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Phase 1 | Status: RECRUITING